Medisun Holdings Limited, with its headquarters in Hong Kong, is a global professional medical investment group that focuses on investing in research, development and commercialization of regenerative medicine and top-tier hospitals and medical centers. Medisun has invested in Cardio3 BioSciences, a Belgian and French stock exchange-listed biotechnology company. Medisun is also actively engaged in clinical development of regenerative therapies in the United States, Japan, Hong Kong and China.
Madison cooperated with the Institute of Human Virology (IHV) of the University of Maryland to set up a platform for the research and development of clinical trials on viruses and cancer. Based on the Madison Biomedical Laboratory in Hong Kong, Madison radiated to build a network of medical clinical trial resources in China and Asia to promote the largest scale of global viral research and cancer treatment technology in Asia. Platform. Madison Regenerative Medical Center is located in Aoteng Square, Kowloon Bay, Hong Kong. It has a 50,000 square feet GMP standard production base for stem cells, a cancer treatment center and an anti-aging center. It brings together experts from Europe, Japan, the United States and individual Chinese nationalities to provide immune cell therapy and a variety of stem cell health courses with a rigorous professional research and development process.